A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease (original) (raw)
Ringden O, Horowitz MM, Gale RP et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993; 270: 57–60. ArticleCASPubMed Google Scholar
Molina AJ, Storb RF . Hematopoietic Stem Cell Transplantation in Older Adults. Martin Duntz Ltd.: London, UK, 2000. Google Scholar
Champlin R, Khouri I, Komblau S et al. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-versus-malignancy effect. Oncology (Huntingt) 1999; 13: 621–628, (discussion 631, 635–638, 641). CAS Google Scholar
Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824. ArticleCASPubMed Google Scholar
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763. CASPubMed Google Scholar
Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562. CASPubMed Google Scholar
McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400. ArticleCASPubMed Google Scholar
Childs RW CE, Tidale J, Plante M et al Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044–2049. ArticlePubMed Google Scholar
Storb R . Nonmyeloablative preparative regimens: experimental data and clinical practice. J Clin Oncol 1998: (Suppl. l): 241–249.
Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536. CASPubMed Google Scholar
Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–637. ArticleCASPubMed Google Scholar
Bacigalupo A, Lamparelli T, Bruzzi P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942–2947. ArticleCASPubMed Google Scholar
Godthelp BC, van Tol MJ, Vossen JM et al. T-cell immune reconstitution in pediatric leukemia patients after allogeneic bone marrow transplantation with T-cell-depleted or unmanipulated grafts: evaluation of overall and antigen-specific T-cell repertoires. Blood 1999; 94: 4358–4369. CASPubMed Google Scholar
Wu CJ, Chillemi A, Alyea EP et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood 2000; 95: 352–359. CASPubMed Google Scholar
Flowers ME, Kansu E, Sullivan KM . Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin N Am 1999; 13: 1091–1112, viii–ix. ArticleCAS Google Scholar
De Lima M, Van Besien KW, Giralt SA et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19: 121–127. ArticleCASPubMed Google Scholar
Radich JP, Gooley T, Sanders JE et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000; 6: 272–279. ArticleCASPubMed Google Scholar
Porter DL, Luger SM, Duffy KM et al. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 230–238. ArticleCASPubMed Google Scholar
Byrne JL, Stainer C, Cull G et al. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant 2000; 25: 411–417. ArticleCASPubMed Google Scholar
Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419–2425. CASPubMed Google Scholar
Ferrara JL . The Pathophysiology of Graft-Versus-Host Disease, Vol. I Blackwell Science, Inc.: Oxford, 1999. Google Scholar
Storb R, Deeg HJ . Failure of allogeneic canine marrow grafts after total-body irradiation. Allogeneic ‘resistance’ versus transfusion-induced sensitization. Transplantation 1986; 42: 571–580. ArticleCASPubMed Google Scholar
Wagner JL, Storb R . Preclinical large animal models for hematopoietic stem cell transplantation. Curr Opin Hematol 1996; 3: 410–415. ArticleCASPubMed Google Scholar
Teshima T, Ferrara JL . Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Semin Hematol 2002; 39: 15–22. ArticlePubMed Google Scholar
Alcindor T, Gorgun G, Miller KB et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 2001; 98: 1622–1625. ArticleCASPubMed Google Scholar
Jabro G, Koc Y, Boyle T et al. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 1999; 5: 173–179. ArticleCASPubMed Google Scholar
Comenzo RL, Malachowski ME, Miller KB et al. Engraftment with peripheral blood stem cells collected by large-volume leukapheresis for patients with lymphoma. Transfusion 1992; 32: 729–731. ArticleCASPubMed Google Scholar
Bryant E, Martin PJ . Documentation of Engraftment and Characterization of Chimerism following Hematopoietic Cell Transplantation. Blackwell Science: Oxford.
Miller KB, Schenkein DP, Comenzo R et al. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 1994; 68: 15–20. ArticleCASPubMed Google Scholar
Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828. CASPubMed Google Scholar
Qamruddin AO, Oppenheim BA, Guiver M et al. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection. Bone Marrow Transplant 2001; 27: 301–306. ArticleCASPubMed Google Scholar
Bearman SI, Appelbaum FR, Back A et al. Regimen-related toxicity and early post transplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288–1294. ArticleCASPubMed Google Scholar
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481. Article Google Scholar
Klangsinsirikul P, Carter GI, Byrne JL et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99: 2586–2591. ArticleCASPubMed Google Scholar
Cull GM, Haynes AP, Byrne JL et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol 2000; 108: 754–760. ArticleCASPubMed Google Scholar
Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071–1078. ArticleCASPubMed Google Scholar
Champlin R, Khouri I, Shimoni A et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18–29. ArticleCASPubMed Google Scholar
Bacigalupo A . Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 2002; 29: 191–195. ArticleCASPubMed Google Scholar
Michallet M, Bilger K, Garban F et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and post transplantation factors on outcome. J Clin Oncol 2001; 19: 3340–3349. ArticleCASPubMed Google Scholar
Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838–1845. CASPubMed Google Scholar
Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720–1728. CASPubMed Google Scholar
Chen F, Maldonado MA, Madaio M et al. The role of host (endogenous) T cells in chronic graft-versus-host autoimmune disease. J Immunol 1998; 161: 5880–5885. CASPubMed Google Scholar
Hale G, Jacobs P, Wood L et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69–76. ArticleCASPubMed Google Scholar
Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181. ArticleCASPubMed Google Scholar
Kumar S, Wolf RC, Chen MG et al. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. Bone Marrow Transplant 2002; 30: 161–165. ArticleCASPubMed Google Scholar
Greinix HT, Volc-Platzer B, Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098–3104. CASPubMed Google Scholar
Greinix HT, Volc-Platzer B, Knobler RM . Extracorporeal photochemotherapy in the treatment of severe graft-versus-host disease. Leukemia Lymphoma 2000; 36: 425–434. ArticleCASPubMed Google Scholar
Gorgun G, Miller KB, Foss FM . Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002; 100: 941–947. ArticleCASPubMed Google Scholar
Chan G, Gorgun G, Miller KB, Foss F . Persistence of host dendritic cells post-transplant is associated with graft versus host disease. Biol Blood Marrow Transplant 2003; 9: 170–176. ArticlePubMed Google Scholar
Ullrich SE . Photoinactivation of T-cell function with psoralen and UVA radiation suppresses the induction of experimental murine graft-versus-host disease across major histocompatibility barriers. J Invest Dermatol 1991; 96: 303–308. ArticleCASPubMed Google Scholar
Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412–415. ArticleCASPubMed Google Scholar
Trotta PP, Tedde A, Ikehara S et al. Specific immunosuppressive effects of constant infusion of 2′-deoxycoformycin. Cancer Res 1981; 41: 2189–2196. CASPubMed Google Scholar
Epstein J, Bealmear PM, Kennedy DW et al. Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2′-deoxycoformycin. Exp Hematol 1986; 14: 845–849. CASPubMed Google Scholar
Kraut EH, Neff JC, Bouroncle BA et al. Immunosuppressive effects of pentostatin. J Clin Oncol 1990; 8: 848–855. ArticleCASPubMed Google Scholar
Jacobsohn DA, Margolis J, Chen AR et al. Pentostatin: a promising treatment for refractory, chronic GVHD. Blood 2001; 98: 399a. Google Scholar
Margolis JH, Jacobsohn DA, Phelps ML et al. Pentostatin: A novel treatment for steroid refractory acute GVHD. Blood 2000; 96: 400a. Google Scholar